Anti-Bribery and Corruption Compliance and Due Diligence

Anti-Bribery and Corruption Compliance and Due Diligence

Strong anti-corruption compliance and due diligence protect your business from regulatory exposure, financial and reputational damage, and costly enforcement.

  • icon

Anti-bribery and corruption laws are now enforced globally, with regulators coordinating across borders and raising expectations of companies. Businesses are facing closer scrutiny not only under the U.S. Foreign Corrupt Practices Act (FCPA) and UK Bribery Act, but also under newer and more assertive regimes in Europe, Asia and beyond. Enforcement activity is expanding, expectations are rising, and you need to show that your company’s programmes and due diligence can withstand global review.

Investigations can be triggered by acquisitions, third-party dealings or operational weaknesses, and lead to significant fines, criminal liability, and reputational harm. Effective compliance programmes and thorough due diligence are critical to staying ahead.

Whether as part of the ordinary course of business, and in M&A transaction or otherwise, we help you design, test and enhance compliance frameworks that are proportionate, practical and credible with regulators. Our lawyers conduct systematic reviews of policies, procedures and internal controls, providing recommendations for improvement and helping you prevent and detect issues.

Global Bribery and Corruption Outlook banner

Global Bribery, Investigations, and Enforcement Outlook 2026

Annual horizon scanning guide to the key corporate crime, investigations and enforcement trends that are expected to impact our clients in the year ahead. The Outlook covers nine areas of focus that speak to five overarching trends including AI in investigations, ESG and supply chain issues, the changing nature of incentivised regulatory cooperation, and more.

Representative experience

6
6
Advising a global e-commerce company on corruption allegations and compliance failures in Germany, including engagement with enforcement authorities.
Representing a multinational pharmaceutical company in ongoing FCPA and anti-corruption investigations in the US and Asia.
Acting for a major European bank in a self-disclosure of potential money laundering and corruption risks.
Advising an Asian conglomerate on a high-profile corruption investigation spanning Germany, the Netherlands, the UK and South Korea.
Assisted a major Japanese conglomerate in conducting thorough anti-corruption due diligence, in relation to the client's high-profile 100% acquisition of a private Vietnamese trading company.
Defending a global auditing firm in Germany in relation to allegations of corruption-linked failures in climate-related audits.
Advising a NASDAQ-listed medical devices business in relation to FCPA, third-party and compliance advice in Japan and Singapore.
Advising a Japanese trading company on FCPA, regulatory and commercial risks in relation to a JV infrastructure project in excess of $2 billion in Bangladesh.
Acting for a medical technology company on a FCPA anti-bribery and corruption due diligence review of a China-based distributor.

You may also be interested in...